2315 Stock Overview
A biotechnology company, engages in the research and development of antibody-based drugs in the People’s Republic of China, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$8.89 |
| 52 Week High | HK$24.20 |
| 52 Week Low | HK$5.74 |
| Beta | 0 |
| 1 Month Change | 2.07% |
| 3 Month Change | -7.88% |
| 1 Year Change | -61.93% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -65.81% |
Recent News & Updates
Is Biocytogen Pharmaceuticals (Beijing) (HKG:2315) A Risky Investment?
May 08
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s (HKG:2315) Price Is Right But Growth Is Lacking
Apr 03Shareholder Returns
| 2315 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -7.0% | -9.1% | -2.6% |
| 1Y | -61.9% | -36.8% | 4.0% |
Return vs Industry: 2315 underperformed the Hong Kong Biotechs industry which returned -36.8% over the past year.
Return vs Market: 2315 underperformed the Hong Kong Market which returned 4% over the past year.
Price Volatility
| 2315 volatility | |
|---|---|
| 2315 Average Weekly Movement | 11.2% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in HK Market | 15.6% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 2315's share price has been volatile over the past 3 months.
Volatility Over Time: 2315's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1,066 | Yuelei Shen | biocytogen.com.cn |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of antibody-based drugs in the People’s Republic of China, the United States, and internationally. Its core products are YH001, a recombinant humanized anti-cytotoxic t-lymphocyte associated protein 4 immunoglobulin G1 (IgG1) monoclonal antibody, which has completed Phase I clinical trial for the treatment of patients with advanced solid tumors; and YH003, a humanized IgG2 agonistic monoclonal antibody that is in Phase II clinical trial for the treatment of unresectable/metastatic mucosal melanoma and pancreatic duct adenocarcinoma, and Phase I clinical trial for the treatment of solid tumors. The company also develops YH002, a recombinant humanized IgG1 antibody that targets the human tumor necrosis factor receptor superfamily, member 4 receptor, which is Phase I clinical trial; YH004, a humanized anti-4- tumor necrosis factor receptor superfamily, member 9 IgG1 antibody that is in Phase I clinical trial for the treatment of advanced solid tumors and relapsed/refractory non-Hodgkin’s lymphoma; and YH008, an anti-PD-1 x cluster of differentiation 40 (CD40) bispecific antibody that is in Phase I clinical trial for the treatment of solid tumors.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Fundamentals Summary
| 2315 fundamental statistics | |
|---|---|
| Market cap | HK$3.55b |
| Earnings (TTM) | -HK$413.51m |
| Revenue (TTM) | HK$774.12m |
4.6x
P/S Ratio-8.6x
P/E RatioIs 2315 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2315 income statement (TTM) | |
|---|---|
| Revenue | CN¥716.91m |
| Cost of Revenue | CN¥206.00m |
| Gross Profit | CN¥510.91m |
| Other Expenses | CN¥893.86m |
| Earnings | -CN¥382.95m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.96 |
| Gross Margin | 71.27% |
| Net Profit Margin | -53.42% |
| Debt/Equity Ratio | 44.4% |
How did 2315 perform over the long term?
See historical performance and comparison